Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention.

Front Cardiovasc Med · 2023 · PMC10501481 · PMID 37719970

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

borderline significantP = 0.054so close (0.05 < p ≤ 0.1)

Purified EPA was associated with a borderline significant reduction of 21.5% in CV risk in the primary endpoint ( P = 0.054) and a significant reduction of 26.6% in the secondary composite endpoint ( P = 0.03) vs. statin monotherapy.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.